Path ID: DB00056_MESH_D015470_3
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:D000079982 | Gemtuzumab ozogamicin | Drug |
| MESH:D000080084 | Calicheamicins | ChemicalSubstance |
| GO:0033028 | Myeloid cell apoptotic process | BiologicalProcess |
| UniProt:P20138 | Myeloid cell surface antigen CD33 | Protein |
| CL:0000763 | Myeloid cell | Cell |
| MESH:D015470 | Acute myeloid leukemia, disease | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Gemtuzumab Ozogamicin | HAS METABOLITE | Calicheamicins |
| Calicheamicins | POSITIVELY REGULATES | Myeloid Cell Apoptotic Process |
| Myeloid Cell Apoptotic Process | NEGATIVELY CORRELATED WITH | Acute Myeloid Leukemia, Disease |
| Gemtuzumab Ozogamicin | DECREASES ACTIVITY OF | Myeloid Cell Surface Antigen Cd33 |
| Myeloid Cell Surface Antigen Cd33 | EXPRESSED IN | Myeloid Cell |
| Myeloid Cell | AFFECTED BY | Acute Myeloid Leukemia, Disease |
Comment: Gemtuzumab ozogamicin is a monoclonal anti-CD33 antibody
Reference: